Navigation Links
Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
Date:11/5/2012

SUNNYVALE, Calif., Nov. 5, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal 2013 first quarter ended September 30, 2012.

Financial Results for First Quarter Ended September 30, 2012 The GAAP (Generally Accepted Accounting Principles) net income for the fiscal quarter ended September 30, 2012 was $75.6 million, or $1.09 and $1.02 per basic and diluted earnings per share, respectively. This compares with a GAAP net loss of $14.5 million, or $0.21 loss per basic and diluted share for the fiscal quarter ended September 30, 2011.

The non-GAAP net income reported for the fiscal quarter ended September 30, 2012 was $78.8 million, or $1.14 and $1.07 income per basic and diluted earnings per share, respectively. This compares with a non-GAAP net loss of $12.4 million, or $0.18 basic and diluted loss per share, for the fiscal quarter ended September 30, 2011. See "Use of Non-GAAP Financial Measures" below for a description of our Non-GAAP measures. Reconciliation between certain GAAP and non-GAAP measures is provided at the end of this press release.

Revenue for the fiscal quarter ended September 30, 2012 was $102.7 million, compared to $37,000 for the fiscal quarter ended September 30, 2011, an increase of approximately $102.7 million. Revenue for the fiscal quarter ended September 30, 2012 consisted primarily of $100 million of license and milestone revenue due to the Company's achievement of two clinical milestones in connection with the Company's collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. ("Janssen").

At September 30, 2012, the Company had cash, cash equivalents and marketable securities of $286.1 million, which compares with $203.6 million at June 30, 2012. Total operating expenses excluding share based compensation during the q
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Neurocrine Biosciences Reports Third Quarter 2012 Results
2. PAREXEL International Reports First Quarter Fiscal Year 2013 Results
3. Global Laparotomy Sponge Market 2011-2015: MarketResearchReports.Biz
4. Global Mobile Health Application Market 2011-2015 : MarketResearchReports.Biz
5. Haemonetics Reports Second Quarter Fiscal 2013 Revenue Up 22%, Organic Revenue Up 6% and Adjusted EPS of $0.90, Reaffirms Fiscal 2013 Guidance and Announces Two-For-One Stock Split
6. Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
7. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
8. InspireMD Reports 2012 Fiscal Year Results
9. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
10. Orthobiologics Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018: China Market Research Reports
11. AFCell Medical Reports Results from the Retrospective Study of a Novel Allograft Membrane to Prevent Post-Operative Adhesions in the Repair of Peroneal and Posterior Tibial Tendons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... -- Decision Resources Group finds that the Latin American ... compound annual growth rate through 2023. This is primarily ... increasing adoption of dental implants. Growing aesthetic consciousness in ... demand for dental biomaterials because they can improve the ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... contrast to traditional LED lights where the spectrum is ... LED technology to incorporate their spectra in a single ... in low proximity installations. The Valoya L-series offers high ... is up to four times longer than commonly used ... clearly higher when compared to traditional fluorescent or LED ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... 11 /PRNewswire-FirstCall/ - MIGENIX Inc. ("MIGENIX"),announced today that ... ("DJohnson"), a significant shareholder of MIGENIX, that will ... shareholders scheduled for,October 31, 2008. As part of ... board of directors from seven members to five ...
... 5:00 p.m. EDT -, VALENCIA, Calif., Aug. 11 ... results for the second,quarter ended June 30, 2008., ... were $80.9,million, compared to $75.4 million for the second ... research and development,(R&D) expenses which totaled $67.6 million for ...
... administrator for the,HealthShares(TM) Indexes, a series of 20 ... announced the following,change effective on the opening of ... Germany: BIO) will replace Speedel Holding AG (SWX,Switzerland: ... AG is being acquired by Novartis AG (SWX, ...
Cached Biology Technology:Migenix averts proxy contest; reaches agreement with DJohnson holdings 2Migenix averts proxy contest; reaches agreement with DJohnson holdings 3Migenix averts proxy contest; reaches agreement with DJohnson holdings 4MannKind Corporation Reports Second Quarter Financial Results 2MannKind Corporation Reports Second Quarter Financial Results 3MannKind Corporation Reports Second Quarter Financial Results 4MannKind Corporation Reports Second Quarter Financial Results 5MannKind Corporation Reports Second Quarter Financial Results 6Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index 2
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... Germans Trias i Pujol Health Sciences Research Institute (IGTP) and ... genetic biomarker to detect Lewy body dementia (LBD), a disease ... in 20% of cases and differentiates one of the sub-groups ... lead to more precise diagnosis and treatment. Lewy body ...
... research from the University of Exeter and King,s College London ... in the contaminated waters of the River Hayle in Cornwall ... to fish from unpolluted sites. The team believe this is ... research was funded by NERC and the Salmon and Trout ...
... , July 25, 2013 The following statement is being issued ... LLP regarding the Pacific Biosciences Securities Litigation SUPERIOR COURT OF ... SAN MATEO IN RE PACIFIC BIOSCIENCES OF ... ACTIONS. Case No. CIV509210 SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION ...
Cached Biology News:Discovered a genetic biomarker that detects Lewy body dementia 2Study investigates extraordinary trout with tolerance to heavily polluted water 2Study investigates extraordinary trout with tolerance to heavily polluted water 3Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 3Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 4
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-rat Dipeptidyl Peptidase IV (DPP IV), CD26, Clone 5E8, Monoclonal Antibody...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
... used to detect the appearance of AcNPV ... cells as early as 8-24 hours post-infection. ... Titer Kit, which allows determination of baculovirus ... The FastPlax Antibody can also be used ...
Biology Products: